Global Pruritus Therapeutics Market Analysis, Key Trends, Growth Opportunities, Challenges And Key Players By 2030

Market Overview:
The global Pruritus Therapeutics Market was estimated at USD 12.11 billion in 2021 and is projected to reach USD 16.37 billion by 2028, growing at a CAGR of 4.4% over the analysis period.

Itchy skin, also known as pruritus, is an uncomfortable and bothersome sensation that triggers the urge to scratch. Dry skin is a common cause of pruritus, particularly among older individuals whose skin tends to dry out as they age. Depending on the underlying cause, itchy skin may appear normal, red, rough, or bumpy. Repeated scratching can lead to thickened, raised skin that may bleed or become infected. Many individuals find relief from self-care methods like regular moisturizing, and using gentle cleansers. The increasing prevalence of chronic diseases and the growing elderly population are the key factors driving the growth of the pruritus therapeutics market in the foreseeable future.

Make confident decisions using our insights and analysis | Request a PDF Sample Report:
https://introspectivemarketresearch.com/request/16231

Key Prominent Players In The Pruritus Therapeutics Market:
• AbbVie Inc.
• Sanofi SA
• Galderma Laboratories LP
• EPI Health LLC
• Cara Therapeutics
• Actavis
• Trevi Therapeutics
• Novartis AG
• Pfizer Inc.
• Merck & Co. Inc.
• Sun Pharmaceuticalc
• GlaxoSmithKlinePLC
• Glenmark Pharmaceuticals Ltd.
• Abbott Laboratories, and Other Major Players.

Market Dynamics:
Driver:
The rising incidence of chronic diseases such as kidney failure, liver disease, cancer, and diabetes contribute to the growing population of individuals experiencing pruritus. As pruritus is a common symptom of these conditions, the demand for effective therapeutics to alleviate itching is expected to rise. Pruritus is more prevalent among older individuals due to age-related factors, including drier skin. With the global increase in the geriatric population, there is a higher likelihood of pruritus cases, driving the demand for therapeutics targeting itch relief in this age group.

Opportunities:
There is a significant opportunity for growth in emerging markets, especially in developing regions where there is a large and underserved patient population. Increasing healthcare infrastructure, improving access to medical care, and raising awareness of pruritus-related conditions present the untapped potential for market expansion in these regions. Despite the availability of various treatment options, there is still an unmet need for more efficacious and safe therapeutics for pruritus. The market offers opportunities for the development of innovative drugs and therapies that can provide better and long-lasting relief from itching, addressing the specific needs of patients.

Read More: https://introspectivemarketresearch.com/reports/pruritus-therapeutics-market/

The Report Will Include A Major Chapter
• Patent Analysis
• Regulatory Framework
• Technology Roadmap
• BCG Matrix
• Heat Map Analysis
• Price Trend Analysis
• Investment Analysis
• Company Profiling and Competitive Positioning
• Industry Value Chain Analysis
• Pestle Analysis
• SWOT Analysis

Segmentation of The Pruritus Therapeutics Market:
The report will help the Pruritus Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, Drug Class, Disease Type, and regions.

By Drug Class
• Calcineurin Inhibitors
• Corticosteroids
• Counterirritants
• Immunosuppressant
• Antihistamines
• Others

By Disease Type
• Allergic Contact Dermatitis
• Atopic Dermatitis
• Psoriasis
• Urticaria
• Others

Regional Analysis Of Pruritus Therapeutics Market
The North American region is anticipated to dominate the pruritus therapeutics market over the forecasted period attributed to the growing prevalence of chronic diseases such as diabetes, eczema, and other skin-related disorders. According to the National Eczema Association, 31.6 million Americans (10.1%) have some form of eczema, with prevalence peaking during childhood. It is also estimated that one in every ten people will develop eczema during their lifetime, with prevalence peaking in childhood. Furthermore, 9.6 million children under the age of 18 in the United States have AD, with one-third suffering from moderate to severe disease. An estimated 16.5 million adults in the United States (7.3%) have AD, with nearly 40% suffering from moderate to severe disease. In addition, 51 million adults in this region are living with diabetes (IDF 2021). This number is expected to reach 57 million by 2030 thus, supporting the development of the pruritus therapeutics market over the projected period.
• North America (U.S., Canada, Mexico)
• Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
• Western Europe (Germany, U.K., France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
• Asia-Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
• Middle East & Africa (Turkey, Saudi Arabia, Bahrain, Kuwait, Qatar, UAE, Israel, South Africa)
• South America (Brazil, Argentina, Rest of SA)

Enquire For Customization in The Report @
https://introspectivemarketresearch.com/custom-research/16231

Key Industry Development In Pruritus Therapeutics Market
In January 2022, AbbVie announced that RINVOQ® (upadacitinib) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease has not responded in comparison to past treatment and is not adequately regulated with other medications or injections.

In January 2022, Galderma announced the acquisition of ALASTIN Skincare, after it received antitrust clearance from U.S. authorities. The patented TriHex Technology®, a proprietary blend of peptides and active botanicals to support the appearance of regenerated skin, supports ALASTIN's product offerings. This acquisition will bolster the position of Galderma in the pruritus therapeutics market.

The report covers exhaustive analysis on:
• The market size and industry growth rate of the global and regional market across various segments
• Based on extensive primary and secondary research this report provides comprehensive and granular data
• Key technological advancements and market trends that shape the market
• Brand dynamics and distribution trends in order to effectively plan strategies in the forecast period 2023-2029
• Key companies operating in the global Pruritus Therapeutics market and their market share

Buy the Latest Version of this Report @

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16231

Read More Related Report: -

https://introspectivemarketresearch.com/reports/gaming-accessories-market/

https://introspectivemarketresearch.com/reports/fenugreek-seed-extract-market/

https://introspectivemarketresearch.com/reports/food-sterilization-equipment-market/

Contact us:
Introspective Market Research
3001 S King Drive,
Chicago, Illinois
60616 USA
Ph no: +1 773 382 1049

About Us:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assist our clients grow and have a successful impact on the market. Our team at IMR is ready to assist our clients flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, specialized in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

This release was published on openPR.